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Elevated permeability of retinal endothelial cells (REC), as observed in diabetic retinopathy (DR), is
induced by extended exposure to 25 ng/ml vascular endothelial growth factor A165 (VEGF165) for up to
3 d and this effect is more pronounced when equimolar amounts of basic ﬁbroblast growth factor (bFGF)
and insulin-like growth factor (IGF-1) are present. Down-regulation of the tight-junction protein claudin-
1 and its loss from the plasma membrane is associated with induced higher permeability, whereas other
tight-junction proteins (e.g. claudin-3, claudin-5, ZO-1) show only subtle changes in our experimental
setting. Using immortalized bovine REC (iBREC) as a well-established model, we investigated effects of
other members of the VEGF family, i.e. VEGF121, placental growth factor (PlGF-1 and PlGF-2) and viral
VEGF-E which activate different sets of VEGF receptors, on barrier function after extended treatment:
iBREC were incubated with 1e100 ng/ml of the growth factors for up to 2 days before barrier function
was assessed by measuring transendothelial resistance (TER). Presence of TJ-proteins was determined by
western blot analyses and immunoﬂuorescence staining. Similar experiments were performed to eval-
uate whether the primary actions of PlGF-1, PlGF-2 or VEGF121 are modulated by bFGF or IGF-1 when all
growth factors (each at 25 ng/ml, but 10 ng/ml IGF-1) act simultaneously at equimolar concentrations.
We also studied the potential normalization of the barrier disturbed with combinations of growth factors
by addition of the VEGF-speciﬁc Fab fragment ranibizumab or the recombinant protein aﬂibercept which
binds VEGF and PlGF. Whereas 1 ng/ml VEGF-E were sufﬁcient to impair the iBREC barrier, a higher
concentration of 100 ng/ml VEGF121 was needed to reduce TER and expression of claudin-1 over 2 days.
By PlGF-1 or PlGF-2, the barrier was not affected even at the highest concentration tested (100 ng/ml)
and these factors also did not modulate the effect of VEGF165. The weak barrier derangement caused by
VEGF121 was slightly enhanced by bFGF and IGF-1. After induction of the barrier breakdown with various
combinations of all growth factors included in the study, normal TER and claudin-1 expression was re-
established by ranibizumab. Both VEGF inhibitors ranibizumab and aﬂibercept similarly reinstated lost
claudin-1, even when applied at a small fraction of the clinically relevant concentrations. These results
show that VEGF-A, but not PlGF impairs the barrier function of iBREC and that the longer isoform
VEGF165 is more potent than VEGF121. To induce barrier dysfunction in iBREC, activation of VEGF receptor
2 e probably in concert with neuropilin-1 e seems to be sufﬁcient because VEGF-E and VEGF165, but not
PlGF-1/-2 reduced TER or claudin-1 expression.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.; (i)BREC, (immortalized) bovine retinal endothelial cells; DME, diabetic macular edema; DR, diabetic retinopathy; EC,
m; ECGS/H, endothelial cells growth supplement/H; FCS, fetal calf serum; IGF-1, insulin-like growth factor; KRN951, N-
0-(5-methyl-3-isoxazolyl)urea; NRP-1, neuropilin-1; PlGF, placental growth factor; REC, retinal endothelial cells; SRM,
ance; TJ, tight junction; VECad, vascular endothelial cadherin; VEGF, vascular endothelial growth factor A; VEGF-E,
eceptor 1; VEGFR2, VEGF receptor 2; ZO-1, zona occludens-1.
ax: þ49 731 500 59192.
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Clinically manifested diabetic retinopathy (DR) is accompanied
by increased proliferation, migration and permeability of retinal
endothelial cells (REC) which most likely result from the deregu-
lated expression of angiogenic growth factors. Particularly, vascular
endothelial growth factor A (VEGF) (Aiello et al., 1994), placental
growth factor (PlGF) (Khaliq et al., 1998), insulin-like growth factor
(IGF-1) (Meyer-Schwickerath et al., 1993), and basic ﬁbroblast
growth factor (bFGF) (Boulton et al., 1997) are considered to play
important roles because elevated levels were found in the vitreous
ﬂuid of DR patients. These growth factors are stimulators of either
proliferation and/or migration as conﬁrmed by in vitro studies with
various types of vascular cells including REC (Castellon et al., 2002;
Deissler et al., 2005, 2008, 2013; Stewart et al., 2011; Yan et al.,
2001). Of the different VEGF-A isoforms, VEGF165 substantially el-
evates permeability of primary or immortalized bovine REC ((i)
BREC)) in vitro (Antonetti et al., 1999; Deissler et al., 2010; Harhaj
et al., 2006). To cause such a disturbance of the iBREC barrier
function, VEGF165 has to be present at a concentration of at least
25 ng/ml (w1.5 nM) (Deissler et al., 2011). VEGF disturbs the barrier
of REC in a time-dependent manner which can be assessed by
measuring the transendothelial resistance (TER) of a conﬂuent
monolayer in vitro: Transient reduction of TER is induced shortly
after addition of VEGF165 in primary or immortalized BREC
(Antonetti et al., 1999; Harhaj et al., 2006; Deissler et al., unpub-
lished observation), but stable reduction of the TER lasting over
several days is observed more than 6 h after addition of VEGF165
(Deissler et al., 2010; Othman et al., 2013). Whereas early changes
in VEGF-induced reduction of TER in primary and immortalized
BREC can be prevented by inhibition of protein kinase C (Harhaj
et al., 2006; Deissler et al., unpublished observation), loss of bar-
rier function induced by extended treatment with VEGF165 cannot
(Deissler et al., 2010). Higher permeability of (retinal) endothelial
cell (EC) layers is always associated with altered intracellular
localization, expression and/or modiﬁcation of tight junction (TJ)-
proteins (Bazzoni, 2006; Cai et al., 2011; Deissler et al., 2008, 2010,
2011; Harhaj et al., 2006; Haurigot et al., 2009; Wisniewska-Kruk
et al., 2012). Short treatment with VEGF165 over minutes to hours
can result in altered localizations of the REC-expressed TJ-proteins
occludin, claudin-3, claudin-5, and ZO-1 (Cai et al., 2011; Harhaj
et al., 2006; Wisniewska-Kruk et al., 2012). However, claudin-1 is
found down-regulated and delocalized from the plasmamembrane
when damaging effects of VEGF165 on REC barrier function over an
extended time period were studied in vitro whereas only subtle
changes were observed for the other TJ-proteins (Deissler et al.,
2008, 2010, 2011).
The effect of the shorter isoform VEGF121 on cellular perme-
ability has not been thoroughly investigated, but previous studies
showed that it is a stimulator of proliferation, but not migration of
REC (Deissler et al., 2008; Stewart et al., 2011). Studies on the in-
ﬂuence of the different PlGF isoforms PlGF-1/-2 on permeability of
microvascular EC are inconclusive: Whereas permeability of
microvascular EC isolated from the porcine brain is elevated after
treatment with PlGF (Vogel et al., 2007), the opposite effect was
seen in human dermal microvascular EC (Brkovic and Sirois, 2007).
PlGF-1 and PlGF-2 also do not disrupt the barrier function of
primary BREC, but PlGF-1 counteracts VEGF-induced barrier
dysfunction in a time-dependent manner (Cai et al., 2011).
Over-expression of IGF-1 in the retina of mice results in an
increased expression of VEGF associated with breakdown of the
blood-retina barrier and loss of the TJ-protein claudin-1 (Haurigot
et al., 2009). However, IGF-1 does not affect the negligibly low
expression of VEGF by un-stimulated (i)BREC (Deissler et al., 2011;
Simorre-Pinatel et al., 1994). Accordingly, the iBREC barrier is notdisturbed by IGF-1 in experiments covering a wide range of con-
centrations around physiological conditions, but when applied
together with bFGF, an intensiﬁed VEGF-induced dysfunction was
observed. This effect is most distinct when the three growth factors
are present in equimolar concentrations of about 1.5 nM (Deissler
et al., 2011).
The members of the VEGF-family initiate intracellular signaling
through binding and activating the different VEGF receptors
VEGFR1, VEGFR2 or neuropilin 1 (NRP-1), all expressed in REC (Cai
et al., 2011; Deissler et al., 2011). VEGF165 as well as VEGF121 activate
VEGFR1 and VEGFR2 (Ferrara, 2004). NRP-1 is a potent receptor for
VEGF165, but is only weakly activated by VEGF121 (Oh et al., 2002;
Pan et al., 2007). Both PlGF-isoforms bind to VEGFR1 and PlGF-2
also activates NRP-1 (Migdal et al., 1998; Park et al., 1994; Sawano
et al., 1996).
VEGF induced permeability of REC is considered causative of
diabetic macular edema (DME) (Nguyen et al., 2006; Qaum et al.,
2001) that may appear at any stage of DR. This condition can be
treated with the VEGF-binding antibody fragment ranibizumab
(Ferrara et al., 2006; Mitchell et al., 2011) or with the recombinant
protein aﬂibercept/VEGF-trap binding also to PlGF (Aiello et al.,
1995; Holash et al., 2002; Do et al., 2012).
Based on these clinical observations and experimental data, we
studied the effects of combinations of different growth factors
(VEGF121, PlGF-1, PlGF-2, bFGF, and IGF-1) with VEGF165 on the
barrier of iBREC. In addition we investigated whether VEGF-
inhibition is sufﬁcient to revert these effects using ranibizumab
or aﬂibercept. This systematic approach including all candidate
factors was chosen to gain a better understanding of their relative
contributions to DME pathophysiology and consequences for
therapies targeting VEGF.
The model of telomerase-immortalized iBREC is well estab-
lished with distinct advantages over primary cells or rodentmodels
(Deissler et al., 2005, 2008, 2010, 2011): Immortalizing primary
cells by ectopic expression of human telomerase reverse tran-
scriptase (TRT) is usually not associated with signiﬁcant changes in
important cellular processes, and the amount of human TRT in
iBREC is similar to that of the bovine homologue expressed in early
passages of primary BREC. Compared to primary cells, it is a distinct
advantage of iBREC that these are free of contaminating cells of
other types allowing more accurate and detailed studies. Further-
more, most relevant proteins are highly conserved between the
human and bovine homologues.
2. Materials and methods
2.1. Reagents, growth factors and antibodies
Recombinant human growth factors bFGF, IGF-1, PlGF-1 (all
E. coli-expressed) and rhVEGF165 (SF21-expressed) were purchased
from R&D Systems (Wiesbaden, Germany); rhVEGF121 (SF21-
expressed) from Calbiochem (Merck, Darmstadt, Germany), and
PlGF-2 (E. coli-expressed) from PeproTech (Hamburg, Germany).
Viral vascular endothelial growth factor-E (VEGF-E; Meyer et al.,
1999) binding to VEGFR2 and NRP-1, and mouse monoclonal anti-
bodies detecting actin were from Abcam (Cambrigde, UK). All
growth factors stimulated proliferation of iBREC verifying their
ability to induce signal transduction (Deissler et al., 2013). Rabbit
polyclonal antibodies binding to human claudin-1 (JAY.8), claudin-3
(Z23.JM), claudin-5 (Z43.JK) or ZO-1 (Z-R1), as well as with
AlexaFluor 594 conjugated detection antibodies (F(ab’)2) were
from Life Technologies (Karlsruhe, Germany) and horseradish
peroxidase-conjugated detection antibodies from BioRad (Munich,
Germany). Rabbit polyclonal antibodies binding to human and
bovine VE-cadherin (VECad) were purchased from Acris (Herford,
H.L. Deissler et al. / Experimental Eye Research 115 (2013) 162e171164Germany). Themodiﬁed Fab fragment ranibizumab (Lucentis,10mg/
ml) (Ferrara et al., 2006) of a humanizedVEGF-binding antibodywas
a gift from Novartis Pharma GmbH (Nuremberg, Germany). Alﬂi-
bercept (Eylea, 40mg/ml; Do et al., 2012) was purchased from Bayer
Pharma (Berlin, Germany). N-(2-Chloro-4-((6,7-dimethoxy-4-
quinolyl)oxy)phenyl)-N0-(5-methyl-3-isoxazolyl)urea (KRN951), a
tyrosine kinase inhibitor speciﬁc for VEGFR1 and VEGFR2
(Nakamura et al., 2006), was obtained from Calbiochem.2.2. Cell cultivation
iBREC e telomerase-immortalized microvascular endothelial
cells from bovine retina e were cultivated in Endothelial Cell
Growth Medium MV (ECGM; Promocell Heidelberg, Germany)
supplemented with 0.4% endothelial cells growth supplement/H
(ECGS/H, 90 mg/ml Heparin), 10 ng/ml epidermal growth factor,
103 nM hydrocortisone and 5% fetal calf serum (FCS) on
ﬁbronectin-coated surfaces (BD Biosciences, Heidelberg, Germany)
as previously described (Deissler et al., 2005, 2011). Expression of
von Willebrand factor, VECad, TJ-proteins claudin-1, -3, -5, ZO-1
and occludin, as well as VEGF receptors VEGFR1, VEGFR2 and
NRP-1 has been conﬁrmed (Deissler et al., 2005, 2008, 2010, 2011).
Although of bovine origin, iBREC can be stimulated with human
recombinant growth factors (Deissler et al., 2005, 2008, 2010, 2011,
2013). Cells used in the experiments were at passages 20 to 35
counting from the stage of primary culture, for which stable
expression of investigated proteins had been conﬁrmed. Under
these conditions, iBREC also formed a conﬂuent monolayer 3 days
after seeding as well as a tight barrier reﬂected by a stable trans-
endothelial resistance of themonolayer of50 Ohm cm2which is
in accordancewith values reported for monolayers of primary BREC
(Deissler et al., 2011; Tretiach et al., 2003).2.3. Treatment of iBREC with growth factors and western blot
analyses
Prior to experiments with conﬂuent iBREC, ECGM was replaced
by serum-reduced medium (SRM) containing 0.4% ECGS/H, 0.25%
FCS, 1 mg/ml ﬁbronectin and 103 nM hydrocortisone for 24 h. Cells
were incubated for up to 3 d with single growth factors (1e100 ng/
ml) or their combinations (each at 25 ng/ml, but 10 ng/ml IGF-1;
corresponding to w 1.5 nM) in SRM, without exchanging the me-
dia during this incubation period, before cell extracts were pre-
pared. To study whether PlGF-1 or PlGF-2 can counteract effects of
VEGF165, iBREC were pretreated with 50 ng/ml VEGF165 for 6 h
before PlGF-1 or PlGF-2 (50e100 ng/ml) were added. Cell extracts
were prepared 42 h later. The potential of the different VEGF-
binding proteins ranibizumab and aﬂibercept to restore barrier
function was also investigated: After treating iBREC with growth
factors for up to 2 d as described above, medium was exchanged
with SRM containing the appropriate growth factors together with
either 0.1e100 mg/ml ranibizumab (w 2 to 2000 nM) or 0.25e25 mg/
ml aﬂibercept (w 2 to 200 nM) before cell extracts were prepared
24 h later. Blocking of barrier damaging by ranibizumab was also
investigated in experiments in which cells were exposed to both
VEGF165 (50 ng/ml) and 1 or 10 mg/ml ranibizumab for 24 h. To
investigate the potential of the speciﬁc VEGFR1/R2 inhibitor
KRN951 to restore barrier function, iBREC were treated with
100 ng/ml VEGF165 for 2 d, before medium was replaced by SRM
supplemented with 100 ng/ml VEGF165 and 0.5e1000 nM KRN951.
Cell extracts were prepared 24 h later. Cell extracts were prepared
and subsequently analyzed by Western blot as described (Deissler
et al., 2011). To verify equal loading of protein, expression of actin
was assessed in parallel.2.4. Transendothelial electrical resistance of cell layers
Transendothelial electrical resistances (TER) of conﬂuent iBREC
monolayers weremeasured as described at several time points (2 h,
4 h, 6 h, 24 h, 30 h, 48 h, 52 h and 72 h) after addition of effectors
(Deissler et al., 2010, 2011). To avoid temperature induced changes
in TER, plates were kept on a warm plate at 37 C during mea-
surements (Blume et al., 2010). Normalized TER values were
calculated in relation to the TER measured in serum-reduced me-
dium just before addition of effectors.
2.5. Immunoﬂuorescence staining
iBREC at a density of 2104 cells/cm2 were allowed to adhere to
two-chamber slides (xWell, Sarstedt, Nuembrecht, Germany)
coated with ﬁbronectin or to ﬁbronectin pre-coated membrane
inserts (0.3 cm2, pore size 0.4 mm; BioCoat, BD Biosciences) in
ECGM. After having formed a conﬂuent monolayer, cells were
treatedwith a growth factormix containing VEGF165, VEGF121, PlGF-
1, PlGF-2, bFGF and IGF-1 (each at 25 ng/ml, but 10 ng/ml IGF-1) in
SRM as described above. Cells were ﬁxed in methanol at 20 C for
15 min and antigens were detected by immunoﬂuorescence
staining as previously described. (Deissler et al., 2007, 2008, 2010)
2.6. General considerations and statistical analyses
Controls were treated in exactly the same way with medium
lacking the effectors. All experiments were repeated several times
and in each experiment data were generated from multiple repli-
cates. The ManneWhitney U test was used to compare sets of
experimental data and differences resulting in p-values below 0.05
were considered signiﬁcant. Results are presented in conventional
boxewhiskers diagrams, with the middle line representing the
mean and the boundaries of the boxes the 75% and 25% percentiles
or the mean and standard deviations are provided.
3. Results
3.1. Different effects of VEGF121, PlGF-1 and PlGF-2 on iBREC barrier
function
The barrier function of iBREC was assessed by measuring the
TER of conﬂuent cells and by Western blot-monitoring of the TJ-
protein claudin-1. We focused on those effects on barrier function
established in the cultures after more than 24 h because changes
observed early after addition of growth factors were considered less
relevant (Blume et al., 2010; Deissler et al., 2010, 2011). VEGF165
decreases TER and claudin-1 expression within 2 days of treatment
at concentrations 25 ng/ml, and it can be detected in the super-
natant of the culture by Western-blot analyses even after extended
incubation (Deissler et al., 2011). Although the related VEGF121 may
also contribute to barrier destabilization in REC, its role has previ-
ously not been investigated. The effects on the TER of conﬂuent
iBREC were therefore measured over 3 days after 10e100 ng/ml
VEGF121 had been added (Fig. 1A). Whereas 10 ng/ml VEGF121 did
not alter TER, concentrations of 25 and 50 ng/ml VEGF121 weakly
but signiﬁcantly reduced TER within 1 or 2 days. This temporary
effect was reversed during prolonged treatment (Fig. 1A). Earliest
changes in TER were observed after treatment for 4 h but this effect
was not signiﬁcant. A stronger and for several days stable reduction
of TER was observed in experiments with 100 ng/ml VEGF121
(Fig. 1A). Compared to 25 ng/ml VEGF165, the effect of VEGF121 on
TER was signiﬁcantly weaker at this concentration (Fig. 1D).
Because of their deregulated expression in DR, we also studied
whether PlGF-1 or PlGF-2 affected permeability of iBREC: Conﬂuent
Fig. 1. Only VEGF165 and VEGF-E strongly disturb the barrier of iBREC. (A)e(C) TER was measured at indicated time points after start of treating conﬂuent iBREC with 1e100 ng/ml
VEGF121 (A), PlGF-1 (B) or VEGF-E (C). Only highest amounts of VEGF121 resulted in a stable decrease of TER. Whereas VEGF-E efﬁciently reduced TER even at 1 ng/ml, PlGF-1 did not
affect TER. Similar results obtained with PlGF-2 are not shown. (D)e(E) Effects of single growth factors (all applied at 25 ng/ml) (D) and various combinations including VEGF165 (E)
on TER of iBREC after 2 d of exposure. VEGF-E was as active as VEGF165 and both were more potent than VEGF121. PlGF-1 and/or PlGF-2 as single agents did not have any effect and
also did not enhance or attenuate the effect of single VEGF165.
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did not inﬂuence TER and this was also observed for PlGF-2 (Fig. 1B
and D, data not shown). Effects induced by treatment with VEGF165
for 2 d were not enhanced or diminished by the PlGFs and the
combined effect of all VEGF-like factors tested was also not signiﬁ-
cantly different from that of VEGF165 (Fig. 1E). It has been suggested
that PlGF-1 but not PlGF-2 abolished VEGF165-induced permeability
of primary BREC when added 6 h after pretreatment with VEGF165
(Cai et al., 2011). To investigate whether this effect is also present
after extended exposure to VEGF165, iBREC were pretreated with
50 ng/ml VEGF165 for 6 h before PlGF-1 or PlGF-2 (50 and 100 ng/ml)
were added. Presence of claudin-1, asmarker for a functional barrier
in iBREC was analyzed by Western-blot analyses in cell extractsprepared 42 h later but its loss was not counteracted by PlGFs
(Supplementary Fig. 1A). TJ-proteins claudin-5 and ZO-1 as well as
VECad were not obviously changed under either condition
(Supplementary Fig. 1A). 50 ng/ml VEGF165 signiﬁcantly reduced
TER after 6 h (normalized TER: 1.0þ 0.08 formedium-treated iBREC
and 0.81þ0.06 for VEGF-treated iBREC; p¼ 0.0027) and addition of
either 100 ng/ml PlGF-1 or PlGF-2 6 h later also did not counteract
further reduction of TERmeasured after 1 d (Supplementary Fig.1B).
Moreover, pretreatment with PlGF-1 or PlGF-2 did not prevent
VEGF165-induced reduction of claudin-1 or TER (data not shown). All
results support the assumption that disruption of the iBREC barrier
is mainly caused by VEGF165 with only minor contributions of PlGFs
and a limited role of the shorter VEGF-A isoform VEGF121.
H.L. Deissler et al. / Experimental Eye Research 115 (2013) 162e171166It could also be concluded that activation of VEGFR2 and/or
NRP-1 might be sufﬁcient to induce barrier dysfunction of iBREC.
Therefore, the impact of the viral VEGF-E on TER was studied,
because this protein activates only these VEGF receptors. VEGF-E
strongly reduced TER with a threshold concentration around
10 ng/ml (Fig. 1C). Compared to 25 ng/ml VEGF165, the effect of
VEGF-E on TER was not signiﬁcantly different at this concentration
(Fig. 1D).Fig. 2. Essentially VEGF165 is responsible for changes in iBREC barrier induced by combinat
IGF-1 (each at 25 ng/ml, but 10 ng/ml IGF-1) without (A, B) or with (C, D) additional PlGF-
expression of TJ-proteins claudin-1, claudin-3, claudin-5, ZO-1 as well as VECad was analyz
Addition of bFGF and IGF-1 slightly enhanced the effect of VEGF121 which was still weaker th
was strongly reduced by VEGF165. This effect was more pronounced in the presence of bFGF
(C) or claudin-1 (D) in the absence of VEGF165. Expression of the other TJ-proteins and of V
claudin-1 for a functional barrier.3.2. Effects of VEGFs and PlGFs in combination with bFGF and IGF-1
on iBREC barrier function
Based on our previous observation that single growth factors
bFGF and IGF-1 do not change barrier properties of iBREC but
slightly stretch the effect of VEGF165 when applied in equimolar
amounts (Deissler et al., 2011), we investigated whether these
factors modulated the transient disturbance induced by VEGF121.ions of growth factors. Conﬂuent iBREC were treated with VEGF165, VEGF121, bFGF and
1 and PlGF-2 (25 ng/ml each) in various combinations for 2 d. TER was measured and
ed by Western blot analyses. (A) VEGF165 but not VEGF121 signiﬁcantly decreased TER.
an that of VEGF165. (B) Only presence of claudin-1 but not of the other proteins tested,
and IGF-1. Supplemented with PlGF-1 and PlGF-2, bFGF and IGF-1 had no effect on TER
ECad did not obviously change under these conditions conﬁrming the importance of
Fig. 3. Plasma membrane localization of claudin-1, but not of claudin-3, claudin-5, ZO-
1 or VECad is lost after growth factor treatment. Conﬂuent iBREC were treated with
VEGF165, VEGF121, PlGF-1, PlGF-2, bFGF and IGF-1 (each at 25 ng/ml, but 10 ng/ml IGF-1)
for 2 d before localization of claudin-1, claudin-3, claudin-5, ZO-1 and VECad was
visualized by immunoﬂuorescence staining. Plasma membrane localization of claudin-
1 is lost after growth factor treatment. Slightly discontinuous staining for VECad, ZO-1
and claudin-5 is observed after growth factor treatment (yellow arrows). In addition,
intracellular gaps can be detected (green arrows). Strong plasma membrane presence
of all other TJ-proteins tested and VECad is seen, conﬁrming a conﬂuent iBREC
monolayer.
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but 10 ng/ml IGF-1) slightly but signiﬁcantly reduced TER whereas
VEGF121 by itself did not signiﬁcantly change TER measured after
treatment for 2 days (Fig. 2A). However, only further addition of
25 ng/ml VEGF165 to this growth factor mix led to a pronounced
decrease in TER (Fig. 2A). After 2 days of treatment, the effect of all
four growth factors on TER treatment was not signiﬁcantly different
from that of single VEGF165 (Fig. 2A). Western-blot analyses of cell
extracts prepared after treatment for 2 d revealed that claudin-1
was completely lost with the combination of VEGF165, VEGF121,
bFGF and IGF-1 and partly lost when VEGF121 plus bFGF and IGF-1
were present (Fig. 2B). Presence of other TJ-proteins as well as
VECad was not obviously changed (Fig. 2B).
The growth factor combination bFGF, IGF-1, PlGF-1 and PlGF-2
also did not signiﬁcantly inﬂuence TER or claudin-1 expression
(Fig. 2C and D): Signiﬁcant reduction of TER was again only seen
when VEGF165 was present and its strong effect was not counter-
acted by PlGF-1 or PlGF-2 (Fig. 2C). Claudin-1 presence e deter-
mined by Western blot analysis e was also strongly reduced only
when VEGF165 was present in the growth factor mix (Fig. 2D).
Obvious changes in the expression of other TJ-proteins and of
VECad were not observed (Fig. 2D).
We have already shown that extended treatment of iBREC with
100 ng/ml VEGF165 results in the loss of claudin-1’s plasma mem-
brane localization whereas only subtle changes for other TJ-
proteins are observed (Deissler et al., 2008, 2011). Immunoﬂuo-
rescence staining of iBREC treatedwith the combination of VEGF165,
VEGF121, bFGF, IGF-1, PlGF-1 and PlGF-2 revealed that the presence
of claudin-1 is completely lost under these conditions (Fig. 3). In
contrast, intense although slightly discontinuous plasma mem-
brane staining was still observed for all the other TJ-proteins tested
(claudin-3, claudin-5, ZO-1) and VECad after growth factor treat-
ment (Fig. 3), conﬁrming the importance of claudin-1 for a func-
tional barrier of iBREC.
3.3. VEGF inhibition is sufﬁcient to restore decreases of TER and
claudin-1 expression induced by VEGF165 combined with other
growth factors
Because only VEGF165 substantially changed barrier properties
of iBREC, we assumed that its inhibition with VEGF-binding rani-
bizumab might re-establish a normal barrier even in the presence
of other growth factors. When clinically relevant amounts of rani-
bizumab (100 mg/ml) were added to iBREC treated for 2 days with
various combinations of VEGF165/121, PlGF-1/2, bFGF and IGF-1, TER
increased signiﬁcantly within 24 h and reached normal values in all
cases after 4 days (Fig. 4A). Ranibizumab also reinstated lost
claudin-1 within 24 h in all experiments (Fig. 4B).
Thepossible surplus beneﬁt of inhibitingall VEGF familymembers
was investigated with the recombinant protein aﬂibercept which
binds VEGF-A and PlGF. Reduction of TER induced by pretreating
iBREC with a mix of VEGF165/121, PlGF-1/2, bFGF and IGF-1 (each at
25 ng/ml, but 10 ng/ml IGF-1) was completely normalized by 25 mg/
ml aﬂibercept (Fig. 5A). To compare their efﬁciencies, aﬂibercept or
ranibizumab were added at various concentrations (2e200 nM) to
the pretreated cells. Of both inhibitors even very low concentrations
(2 nM; corresponding tow 0.1 mg/ml ranibizumab orw 0.25 mg/ml
aﬂibercept) in comparison to those achieved in DR therapy
were sufﬁcient to reinstate lost claudin-1 completely (Fig. 5B).
3.4. Speciﬁc inhibition of VEGF receptor tyrosine kinases is not
sufﬁcient to restore VEGF-induced barrier disturbance
The observations that VEGF-E induced permanent changes as
efﬁcient as VEGF165 (Fig. 1C and D) and that the effect of VEGF121was weaker and transient (Fig. 1A and D), suggested a crucial
involvement of VEGFR2 and/or NRP-1 in barrier impairment.
Accordingly, pretreatment of iBREC with the speciﬁc inhibitor
KRN951 prevented VEGF-induced loss of claudin-1 at a concen-
tration (0.5 nM) sufﬁcient to inhibit VEGFR2 and VEGFR1 (Deissler
et al., 2011; Nakamura et al., 2006). To answer the question
whether inhibition of the VEGF receptor tyrosine kinases is also
sufﬁcient to restore already lost claudin-1, iBREC were pretreated
with VEGF165 before KRN951 (0.5 nMe1 mM) or ranibizumab (1e
10 mg/ml) were added for 24 h (Fig. 6). To completely restore
claudin-1, 100-times higher concentrations of KRN951 (>50 nM)
were necessary than to prevent its loss (Fig. 6A), but at this con-
centration the inhibitor likely affects other tyrosine kinases
(Nakamura et al., 2006). In contrast, preventing and re-instating
loss of claudin-1 were both achieved with similar amounts of
ranibizumab (Fig. 6B).
Fig. 4. TER and claudin-1 decreased by growth factor mixes are restored by inhibition of VEGF. (AeB): iBREC were pretreated with various growth factor combinations (each at
25 ng/ml, but 10 ng/ml IGF-1) for 2 d before medium was changed to medium with additional 100 mg/ml ranibizumab. (A) TER was measured 4 days after addition of ranibizumab
which then had completely restored normal TER. (B) Normal claudin-1 expression was also re-instated by treatment with ranibizumab for 1 d in all experimental settings.
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In our previous studies we showed that extended treatment of
REC for up to 3 d with the isoform VEGF165 directly results in a
reduced TER associated with lost expression of claudin-1 whereas
expression and cellular localization of other TJ-proteins or VECad
are only subtly inﬂuenced (Deissler et al., 2008, 2010, 2011).
Extending these investigations, potentially relevant effects of other
members of the VEGF family were considered. Rather than study-
ing short-term effects (Cai et al., 2011; Harhaj et al., 2006), cells
were observed over several days likely corresponding to the in vivo
situation in DR patients (Deissler et al., 2008, 2010, 2011). Growth
factors and VEGF inhibitors were used at concentrations low
enough to exclude non-speciﬁc effects and presence of VEGF165
after treatment for 3 d in the culture supernatant has been
conﬁrmed (Deissler et al., 2011). As an indicator of barrier function,
the TER of iBRECmonolayers was determined. This indirect method
is non-invasive and has the distinct advantage that the same cul-
ture can be monitored easily during long-term experiments by
multiple subsequent measurements. Quantifying the ﬂux of labeled
macromolecules of different sizes through a monolayer of REC is a
more direct approach to assess barrier function (Cai et al., 2011;
Harhaj et al., 2006). However, the repetitive addition of dye-
labeled macromolecules is associated with more frequent ex-
changes of the culture medium which might undesirably disturb
the cultivated cells in experiments over several days. Both methodswere used to study short-term (up to 1 d) exposures of REC to
growth factors (Cai et al., 2011). Results of this investigation
conﬁrmed that at least for experiments of the described type, TER
and ﬂux measurements can be considered equivalent to examine
barrier function.
All growth factors stimulated proliferation and/or migration of
iBREC, thereby conﬁrming that the used recombinant human
polypeptides can activate their relevant bovine growth factor re-
ceptors (Deissler et al., 2005, 2008, 2013). The shorter isoform
VEGF121 only weakly and transiently disturbed the iBREC barrier
function, even shortly after addition of the growth factor. Limited
relevance of VEGF121 in the regulation of permeability in endo-
thelial cells was also shown for human dermal microvascular EC
(Brkovic and Sirois, 2007) and macrovascular EC (Becker et al.,
2005). In accordance with previous studies on primary BREC (Cai
et al., 2011), the VEGF-related PlGFs did not show any direct ef-
fect on iBREC barrier. Interestingly, PlGF also does not induce
permeability in human dermal microvascular EC (Brkovic and
Sirois, 2007) but in microvascular EC of the porcine brain (Vogel
et al., 2007) indicating that similar behavior even of microvas-
cular EC of different origin is not always seen. Additive or coun-
teracting modulations of VEGF165’s actions by PlGF-1/PlGF-2 or
VEGF121 were also not observed in primary (Cai et al., 2011) and
immortalized BREC when the growth factors were added simulta-
neously, suggesting that these factors play indeed a minor role in
barrier impairment in REC. However, the suggested interference of
Fig. 5. Ranibizumab and aﬂibercept restore normal barrier function with similar efﬁ-
ciency. (A): Conﬂuent iBREC were treated with VEGF165, VEGF121, PlGF-1, PlGF-2, bFGF
and IGF-1 (each at 25 ng/ml, but 10 ng/ml IGF-1) for 1 d. During further incubation
with additional 25 mg/ml aﬂibercept for 1 d, the decreased TER was completely
reverted. (B) iBREC were treated with growth factors and inhibitors aﬂibercept or
ranibizumab as described above. Then claudin-1, claudin-5, ZO-1 as well as VECad
were analyzed by Western blot. Both inhibitors restored lost claudin-1 with similar
efﬁciencies. Expression of the other proteins tested was not obviously affected.
Fig. 6. Speciﬁc inhibition of VEGFR1 or VEGFR2 is not sufﬁcient to restore a normal
barrier after damaging with VEGF165. (A) Conﬂuent iBREC were treated with VEGF165
for 2 d before 0.5e1 mM KRN951 were added. At least 50 nM KRN951 were needed to
completely restore lost claudin-1 and at this concentration KRN951 likely inhibits also
other tyrosine kinases. (B) iBREC were incubated with VEGF165 and ranibizumab or
pretreated with the growth factor before ranibizumab was added. The VEGF165-
induced loss of claudin-1 was completely prevented or restored by 10 mg/ml
ranibizumab.
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in primary BREC (Cai et al., 2011) was not observed in our experi-
mental setting, most likely explained by different concentrations of
vital components (e.g. hydrocortisone, FCS, heparin and ﬁbro-
nectin) used in the culture medium which might inﬂuence the
action of VEGF165 and/or PlGF on REC.
We have already shown that IGF-1 or bFGF did not alter iBREC’s
TER and claudin-1 expression after extended growth factor treat-
ment (Deissler et al., 2011). Their potential contribution to an
overall effect by weakly enhancing the effect of VEGF121 also seems
not relevant in the presence of the dominating factor VEGF165. The
key role of VEGF-A isoforms was strongly supported by our resultsshowing that even when all growth factors tested were present,
altered TER and TJ-composition could be completely reversed by
inhibition with ranibizumab without targeting the other factors.
Accordingly, inactivation of both VEGF-A and PlGFs with aﬂibercept
was equally effective but not superior under these conditions. To
reinstate lost claudin-1, surprisingly low concentrations of ranibi-
zumab or aﬂibercept considerably below the pharmacologically
achievable values were sufﬁcient. Complete loss of claudin-1’s
plasma membrane localization but only subtle discontinuous
staining for all other TJ-proteins tested was observed after growth
factor treatment which is in accordance with previous observations
after prolonged VEGF-treatment conﬁrming claudin-1’s impor-
tance for a functional iBREC barrier (Deissler et al., 2008, 2010;
Wisniewska-Kruk et al., 2012). Whether loss of claudin-1 pres-
ence is associated with an altered phosphorylation pattern of the
protein is unclear. However, the putative phosphorylation site
Thr203 which regulates plasma membrane localization of rodent
claudin-1 (Fujibe et al., 2004), is not present in the human or bovine
protein which are identical in the C-terminal region of the protein.
Our results also suggest that VEGFR2 e possibly in concert with
NRP-1 e is crucially involved in VEGF-induced impairment of the
REC barrier: When used at physiologically relevant concentrations,
VEGF165 and VEGF-E induced a strong and permanent reduction of
TER and claudin-1, the effect of VEGF121 was weak and transient,
and PlGF-1/-2 did not affect permeability at all. Based on these
observations, we hypothesize that activation of VEGFR2 e but not
VEGFR1 e is sufﬁcient to initiate barrier disruption which is sup-
ported by experiments showing that speciﬁc inhibition of VEGFR1/
2 prevents VEGF-induced loss of claudin-1 in iBREC (Deissler et al.,
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inhibition of VEGF receptor tyrosine kinases prevents VEGF-
induced loss of claudin-1 in iBREC (Deissler et al., 2011). However,
NRP-1 probably strengthens the action of VEGFR2 and persistence
of barrier break-down very likely requires bridging between NRP-1
and VEGFR2. This conclusion is based on the facts that selective
inhibition of VEGFR1/2 was barely sufﬁcient to restore the VEGF165-
induced loss of claudin-1 and that VEGF121 which binds weakly to
NRP-1 and cannot ligate NRP-1 to VEGFR2 (Pan et al., 2007),
induced only transient changes. In macrovascular EC, NRP-1 regu-
lates VEGF-induced permeability (Becker et al., 2005) and bridging
between NRP-1 and VEGFR2 appears to be necessary to stimulate
migration in these cells (Pan et al., 2007). In contrast, an important
and independent role of VEGFR1 in the VEGF-induction of a barrier
dysfunction in iBREC seems rather unlikely because both PlGF-
isoforms did not have any effect. Contrary to these results, an
involvement of VEGFR1 has been suggested, but in these studies
cells from different origin (porcine brain EC) were used (Vogel et al.,
2007).
Interestingly, iBREC migration was more strongly stimulated by
VEGF-A together with PlGF compared to VEGF-A alone, although
both PlGF-isoforms as single agents had no effect (Deissler et al.,
2013). Cross-activation of VEGFR2 by PlGF-activated VEGFR1
shortly after addition of the growth factor has been demonstrated
in studies on angiogenesis in microvascular EC (Autiero et al.,
2003). The physiologically occurring heterodimer VEGF165/PlGF as
well as the homodimer VEGF165 induce heterodimerization of
VEGFR1 and VEGFR2 within minutes after treatment thereby also
stimulating angiogenesis EC (Autiero et al., 2003). Whether cross
activation or heterodimerization of the VEGF receptors are involved
in the disruption of the endothelial cell barrier after prolonged
treatment remains to be shown. The inability of PlGF-1/-2 to
enhance VEGF-induced barrier dysfunction in (i)BREC suggests that
an important contribution of cross activation by PlGF-activated
VEGFR1 is rather unlikely when “long-term” effects are concerned.
Our study revealed that aﬂibercept and ranibizumab are simi-
larly efﬁcient in restoring barrier function of REC after extended
treatment with growth factor mixes containing VEGF-A, PlGF, bFGF
and IGF-1. Interestingly, superiority of additional inhibition of PlGF
in treatment of DME using aﬂibercept could not be demonstrated in
clinical investigations (Do et al., 2012). Taken together, a dominant
role of VEGF-A in the disturbance of the blood-retina barrier
observed in DME may be concluded although involvement of other
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